<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523860</url>
  </required_header>
  <id_info>
    <org_study_id>IIL_FLE09</org_study_id>
    <nct_id>NCT01523860</nct_id>
  </id_info>
  <brief_title>Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma</brief_title>
  <acronym>FLE09</acronym>
  <official_title>Brief Induction Chemoimmunotherapy With Rituximab + Bendamustine + Mitoxantrone Followed by Rituximab in Elderly Patients With Advanced Stage Previously Untreated Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter phase II trial designed to determine efficacy and safety
      of a brief chemoimmunotherapy with the combination of Rituximab + Bendamustine + Mitoxantrone
      in elderly patients with advanced stage Follicular Lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (CR) Rate at the end of the consolidation phase</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of CR according to the Cheson 2007 response criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS will be measured from the day of enrolment to the date of disease progression, relapse or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular response rate (Bcl2/IgH rearrangement)</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of conversion to molecular remission by qualitative and quantitative PCR only in patients with a positive marker at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular relapse rate</measure>
    <time_frame>24 moths</time_frame>
    <description>Rate of conversion to molecular relapse measured by PCR only in patients with a positive marker at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3 or greater overall toxicities measured by CTCAE v.3.0</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 moths</time_frame>
    <description>OS will be measured from the day of enrolment to the date of death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab, Mitoxantrone, Bendamustine</intervention_name>
    <description>Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological proven diagnosis of B-cell CD20+ follicular NHL, grade I, II and IIIa of
             WHO Classification

          -  Untreated patients with the exception of prior limited radiotherapy

          -  Stage III or IV who require therapy according to SIE and GELF criteria

          -  Stage II with at least one of the following:

               -  Bulky disease (&gt;7 cm)

               -  LDH &gt;normal

               -  Systemic symptoms

               -  Beta2-Microglobulin &gt;3 mg/l

               -  Extra-nodal involvement

               -  Active disease with rapid progression 5.Age from 65 to 80 years, geriatric score
                  &quot;FIT&quot; (see Appendix B) 6.Life expectancy &gt;6 months 7.ECOG performance status 0-2
                  (see Appendix C) 8.LVEF ≥45% or FS ≥37% 9.ANC ≥1 x 109/l and Platelets count ≥75
                  x 109/l, unless due to bone marrow involvement by follicular lymphoma
                  10.Creatinine up to 1.5 x ULN 11.Conjugated bilirubin up to 2 x ULN 12.Alkaline
                  phosphatase and transaminases up to 2 x ULN 13.Sending of bone marrow sample for
                  Bcl-2/IgH rearrangement evaluation 14.Written informed content

        Exclusion Criteria:

          -  Men not agreeing to take adequate contraceptive precautions during and for at least 6
             months after cessation of therapy

          -  History of other malignancies within 3 years prior to study entry except for:
             adequately treated carcinoma in situ of the cervix; basal or squamous cell skin
             cancer; low grade, early stage, localized prostate cancer treated surgically with
             curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with
             curative intent

          -  Medical condition requiring long term use (&gt;1 months) of systemic corticosteroids

          -  Active bacterial, viral, or fungal infection requiring systemic therapy 5. Concurrent
             medical condition which might exclude administration of therapy

          -  Cardiac insufficiency (NYHA grade III/IV; see Appendix D)

          -  Myocardial infarction within 6 months of entry on study

          -  Severe chronic obstructive pulmonary disease with hypoxemia

          -  Severe diabetes mellitus difficult to control with adequate insulin therapy

          -  Hypertension that is difficult to control

          -  Impaired renal function with creatinine clearance &lt;30 ml/min (see Appendix E)

          -  HIV positivity

          -  HBV positivity with the exception of patients HbsAg negative and Ab anti-Hbcore
             positive (these patients need to receive prophylaxis with Lamivudine)

          -  HCV positivity with the exception of patients with no laboratory signs of active
             chronic hepatitis and HCV-RNA negativity

          -  CNS involvement by lymphoma 16. Participation at the same time in another study in
             which investigational drugs are used

          -  Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins

          -  Any other co-existing medical or psychological condition that would preclude
             participation in the study or compromise ability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Vitolo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Azienda Sanitaria Ospedaliera-Universitaria S. Giovanni Battista - TORINO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)</name>
      <address>
        <city>Meldola</city>
        <state>Forlì-Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e Trapianto Ospedale Card.Panico</name>
      <address>
        <city>Tricase</city>
        <state>Lecce</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia, A.O. San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>Milano</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica ed Ematologia, Istituto Clinica Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncologia Medica A, Centro di Riferimento Oncologico</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Oncologia ed Onco-Ematologia, Ospedale di Rimini</name>
      <address>
        <city>Rimini</city>
        <state>Rn</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale SS. Antonio e Biagio</name>
      <address>
        <city>Alessandria</city>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOS Ematologia Ospedale C. Massaia</name>
      <address>
        <city>Asti</city>
        <zip>14100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia con Trapianto, Università di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicina Interna, Ospedale degli Infermi</name>
      <address>
        <city>Biella</city>
        <zip>13800</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia e TMO, Ospedale di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. di Ematologia, Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia, Ospedale Businco</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia, Ospedale di Catania</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Santa Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica Policlinico Carreggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia, Policlinico Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia I, A.O.U. San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Medicina Trasfusionale ed Ematologia , P.O. Ivrea</name>
      <address>
        <city>Ivrea</city>
        <zip>10015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia, Azienda Ospedaliera Papardo</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia, Ospedale Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico La Marcora</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia, II Facoltà di Medicina e Chirurgia Università Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCDU Ematologia, AOU Maggiore della Carità</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UO Ematologia, Università - Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale Santa Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Div. Ematologia A.O. &quot;Bianchi Melacrino Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento di biotecnologie cellulari ed ematologia Ospedale Umberto I, Università La Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria di Terni</name>
      <address>
        <city>Terni</city>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. San Giovanni Battista - Biologia Molecolare</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osp. San Giovanni Battista - Ematologia 2</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Chiara</name>
      <address>
        <city>Trento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ematologia Ospedale Santa Maria Di Ca' Foncello</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica di Ematologia, A.O.U. di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>February 29, 2016</last_update_submitted>
  <last_update_submitted_qc>February 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

